Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New US ambulatory electrocardiograph standard:

This article was originally published in Clinica

Executive Summary

The Association for the Advancement of Medical Instrumentation (AAMI) in the US has released a revision of the Ambulatory Electrocardiographs American National Standard which focuses on minimum requirements for safety and effectiveness of ECG equipment. Approved by the American National Standards Institute, the revised ANSI/AAMI EC38 standard covers how to effectively obtain a cardiac rhythm signal from the surface of a patient's body and transmit the signal to a recording device. Updates to the document include changes to the sections pertaining to stationary equipment, defibrillator energy shunting and an expanded section on electromagnetic compatibility. It will be especially useful to device purchasers, says AAMI, because it provides a precise description of the characteristics and limitations of ambulatory ECG equipment.

You may also be interested in...



COVID-19 Vaccines Donated To Philippines Require Emergency Use Authorization

Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.

Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders

Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.

Sandoz Pioneers Posaconazole And Silodosin In Canada

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel